Inozyme Pharma
ENPP1 enzyme replacement therapy (INZ-701) for rare calcification disorders
- Sector
- Biotech
- Headquarters
- BOSTON, MA
- Founded
- 2015
- Latest Form D
- $10.7M, Nov 2018
- Total capital
- $10.7M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $10.7M
- 2 Form D · last Nov 2018
- 95 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 2
- 29 pending · first 2023
- Rank in peer group#397 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$10.7M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
1 record has no date or no amount, so it isn’t placed on the timeline.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#397 · top 27%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Axel BolteExecutive Officer, DirectorNamed in SEC Form D filings
- Douglas TrecoDirectorNamed in SEC Form D filings
- Edward MathersDirectorNamed in SEC Form D filings
- Joseph SchlessingerDirectorNamed in SEC Form D filings
- Lynne SullivanDirectorNamed in SEC Form D filings
- Martin EdwardsDirectorNamed in SEC Form D filings
Show all 9 people
- Reinaldo DiazDirectorNamed in SEC Form D filings
- Rob HopfnerDirectorNamed in SEC Form D filings
- Sarah BhagatDirectorNamed in SEC Form D filings
What it has protected
USPTO · 2 granted of 31- PendingNPP1 Fusion ProteinsUSPTOApplication 19183431
- PendingTreatment Of ENPP1 Deficiency And ABCC6 DeficiencyUSPTOApplication 18904807
- PendingLyophilized ENPP1 Polypeptide Formulations And Uses ThereofUSPTOApplication 18612571
Show all 31 patent records
- NPP1 Fusion ProteinsJan 22, 2026 · Application 19183431Pending
- Treatment Of ENPP1 Deficiency And ABCC6 DeficiencyMay 29, 2025 · Application 18904807Pending
- Lyophilized ENPP1 Polypeptide Formulations And Uses ThereofMar 6, 2025 · Application 18612571Pending
- Methods Of Improving Cardiovascular Function And Treating Cardiovascular Disease Using A Recombinant Ectonucleotide Pyrophosphatase Phosphodiesterase (NPP1)Jan 16, 2025 · Application 18904634Pending
- Methods Of Improving Cardiovascular Function And Treating Cardiovascular Disease Using A Recombinant Ectonucleotide Pyrophosphatase Phosphodiesterase (NPP1)Nov 5, 2024 · US 12,134,790Granted
- Treatment of ENPP1 Deficiency and ABCC6 DeficiencyJun 6, 2024 · Application 18319821Pending
- Methods Of Treating Tissue CalcificationMay 16, 2023 · US RE49,529Granted
- NPP1 Fusion ProteinsApr 27, 2023 · Application 17819065Pending
- NPP1 Fusion ProteinsSep 30, 2021 · Application 17105245Pending
- Treatment of ABCC6 DeficiencyApplication 63237351Pending
- Treatment of ENPP1 DeficiencyApplication 63219229Pending
- Treatment of ENPP1 DeficiencyApplication 63116086Pending
- Treatment of diseases of pathological calcificationApplication 63116093Pending
- Treatment of ABCC6 DeficiencyApplication 63116106Pending
- Compositions And Methods For Preventing Or Inhibiting Intimal ProliferationApplication 63047865Pending
- Compositions And Methods For Treating Allograft VasculopathyApplication 63047793Pending
- Compositions And Methods For Treating Moyamoya Disease And Moyamoya SyndromeApplication 63047877Pending
- Compositions And Methods For Treating Allograft VasculopathyApplication 63047848Pending
- Treatment Of Diseases Involving Deficiency Of ENPP1 Or ENPP3Application 62877044Pending
- Treatment Of Diseases Involving Deficiency Of ENPP1 Or ENPP3Application 62821692Pending
- Treatment Diseases Involving Deficiency of ENPP1 or ENPP3Application 62794450Pending
- Treatment Of ENPP1 Deficiency And ABCC6 Deficiency In InfantsApplication PCTUS2025031978Pending
- Treatment Of ENPP1 Deficiency And ABCC6 Deficiency In ChildrenApplication 19512793Pending
- Compositions And Methods For Treatment Of CalciphylaxisApplication 63717958Pending
- Treatment Of ENPP1 Deficiency And ABCC6 Deficiency In InfantsApplication 63655302Pending
- Treatment Of ENPP1 Deficiency And ABCC6 Deficiency In ChildrenApplication 63578137Pending
- Treatment Of ENPP1 Deficiency And ABCC6 DeficiencyApplication PCTUS2023065340Pending
- Lyophilized ENPP1 Polypeptide Formulations And Uses ThereofApplication PCTUS2022076969Pending
- Treatment of ENPP1 Deficiency and ABCC6 DeficiencyApplication 63327215Pending
- Treatment Of ENPP1 Deficiency And ABCC6 DeficiencyApplication PCTUS2021060207Pending
- Lyophilized ENPP1 Polypeptide Formulations And Uses ThereofApplication 63248303Pending
Related companies, and why
- Aloe Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
- MYOGENICA INC.Similar federal contract value in Biotech · null in contracts
- Oisin Biotechnologies, Inc.Similar federal contract value in Biotech · null in contracts
- Encepheal Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- PELICAN THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- Acomhal Research, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .